Multiple endocrine neoplasia type 1 caused by mosaic mutation: clinical follow-up and genetic counseling?

in European Journal of Endocrinology
View More View Less
  • 1 Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 – CANTHER – Cancer – Heterogeneity Plasticity and Resistance to Therapies, Lille, France
  • | 2 Genetics Department, Hospices Civils de LYON (HCL), University Hospital, East Pathology Center, Lyon, France
  • | 3 Service de Génétique et Biologie Moléculaires, Hôpital Cochin, DMU BioPhyGen, Assistance Publique-Hôpitaux de Paris, AP-HP, Centre-Université de Paris, Paris, France
  • | 4 Institut Cochin, Inserm U1016, CNRS UMR8104, Université de Paris, CARPEM, Paris, France
  • | 5 Aix Marseille Univ, APHM, INSERM, MMG, Laboratory of Molecular Biology Hospital La Conception, Marseille, France
  • | 6 Endocrinology, Diabetology and Nutrition Unit, University Hospital of Reims, Reims, France
  • | 7 Inserm/CNRS UMR 1283/8199, Pasteur Institute of Lille, EGID, Lille, France
  • | 8 Cabinet Médical, Rue de Sarre, METZ, France
  • | 9 CHU Lille, Service d’Endocrinologie, Diabétologie, Métabolisme et Nutrition, Hôpital Claude Huriez, Lille, France
  • | 10 CH Cornouaille Quimper – Service d’Endocrinologie, Quimper, France
  • | 11 Department of Gastroenterology and Digestive Oncology, Reims University Hospital, Reims, France
  • | 12 Service d’Endocrinologie, Centre Hospitalier Universitaire, Hôpital du Haut Levêque, Pessac, France
  • | 13 Service Endocrinologie, CHU de Nancy, Hôpital de Brabois, Vandoeuvre-lès-Nancy, France
  • | 14 CHU Lille, Service de Biochimie et Biologie moléculaire ‘Hormonologie, Métabolisme-Nutrition, Oncologie’, Lille, France
  • | 15 Univ. Lille, Inserm, CHU Lille, U1286 – Infinite – Institute for Translational Research in Inflammation, Lille, France

Correspondence should be addressed to P Romanet; Email: pauline.romanet@univ-amu.fr
Restricted access

USD  $0.00
USD  $0.00

USD  $0.00
USD  $0.00

MEN1 is an autosomal dominant hereditary syndrome characterized by several endocrine tumors, in most cases affecting the parathyroid glands, pancreas, and anterior pituitary. It is the result of inactivating mutations in the tumor suppressor gene MEN1. More than 1300 different mutations have been identified in this gene. Mosaic MEN1 mutations have been previously described in only a few patients in the literature. In this paper, we provide a review of six cases of MEN1 mosaicism reported in the literature supplemented with six additional cases described by the French TENgen network of laboratories. This review highlights that (i) MEN1 mosaicism is not associated with a mild phenotype and results in the same natural history as heterozygous MEN1 mutation and (ii) that more systematic detection of MEN1 mosaic mutation enables improvements in both patient monitoring and genetic counseling.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 85 85 85
Full Text Views 4 4 4
PDF Downloads 5 5 5
  • 1

    Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA & Liotta LA et al.Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997 276 404407. (https://doi.org/10.1126/science.276.5311.404)

    • Search Google Scholar
    • Export Citation
  • 2

    Wermer P Genetic aspects of adenomatosis of endocrine glands. American Journal of Medicine 1954 16 363371. (https://doi.org/10.1016/0002-9343(5490353-8)

    • Search Google Scholar
    • Export Citation
  • 3

    Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P, Niccoli P, Ménégaux F, Chabrier G & Borson-Chazot F et al.Risk factors and causes of death in MEN1 disease: a GTE (groupe d’Etude des tumeurs endocrines) cohort study among 758 patients. World Journal of Surgery 2010 34 249255. (https://doi.org/10.1007/s00268-009-0290-1)

    • Search Google Scholar
    • Export Citation
  • 4

    Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F & Brandi ML et al.Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). Journal of Clinical Endocrinology and Metabolism 2012 97 29903011. (https://doi.org/10.1210/jc.2012-1230)

    • Search Google Scholar
    • Export Citation
  • 5

    Lourenço DM, Toledo RA, Coutinho FL, Margarido LC, Siqueira SA, dos Santos MA, Montenegro FL, Machado MC, Toledo SP. The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1. Clinics 2007 62 465476. (https://doi.org/10.1590/S1807-59322007000400014)

    • Search Google Scholar
    • Export Citation
  • 6

    Pieterman CRC, Schreinemakers JMJ, Koppeschaar HPF, Vriens MR, Rinkes IHMB, Zonnenberg BA, van der Luijt RB, Valk GD. Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome. Clinical Endocrinology 2009 70 575581. (https://doi.org/10.1111/j.1365-2265.2008.03324.x)

    • Search Google Scholar
    • Export Citation
  • 7

    Ramundo V, Milone F, Severino R, Savastano S, Di Somma C, Vuolo L, De Luca L, Lombardi G, Colao A, Faggiano A. Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients. Hormone and Metabolic Research 2011 43 794800. (https://doi.org/10.1055/s-0031-1286324)

    • Search Google Scholar
    • Export Citation
  • 8

    Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Annals of Internal Medicine 1998 129 484–494. (https://doi.org/10.7326/0003-4819-129-6-199809150-00011)

    • Search Google Scholar
    • Export Citation
  • 9

    Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Human Mutation 2008 29 2232. (https://doi.org/10.1002/humu.20605)

    • Search Google Scholar
    • Export Citation
  • 10

    Odou MF, Cardot-Bauters C, Vantyghem MC, Carnaille B, Leteurtre E, Pigny P, Verier-Mine O, Desailloud R, Porchet N. Contribution of genetic analysis in screening for MEN1 among patients with sporadic disease and one or more typical manifestation. Annales d’Endocrinologie 2006 67 581587. (https://doi.org/10.1016/s0003-4266(0673010-4)

    • Search Google Scholar
    • Export Citation
  • 11

    Tham E, Grandell U, Lindgren E, Toss G, Skogseid B, Nordenskjöld M. Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. Journal of Clinical Endocrinology and Metabolism 2007 92 33893395. (https://doi.org/10.1210/jc.2007-0476)

    • Search Google Scholar
    • Export Citation
  • 12

    Klein RD, Salih S, Bessoni J, Bale AE. Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory. Genetics in Medicine 2005 7 131138. (https://doi.org/10.1097/01.gim.0000153663.62300.f8)

    • Search Google Scholar
    • Export Citation
  • 13

    Farook S, Kannappan D, Kenz S, Lalloo F, Trainer P, Brabant G. MEN-1 mosaic: the founder of a family. Endocrine Abstracts 2011 25 P196.

  • 14

    Mauchlen R, Carty D, Talla M, Drummond R. Multiple endocrine neoplasia type 1 (MEN1) mosaicism caused by a c.124G>A variant in the MEN1 gene. Endocrine Abstracts 2019 65 CC4. (https://doi.org/10.1530/endoabs.65.CC4)

    • Search Google Scholar
    • Export Citation
  • 15

    Coppin L, Ferrière A, Crépin M, Haissaguerre M, Ladsous M, Tabarin A, Odou MF. Diagnosis of mosaic mutations in the MEN1 gene by next generation sequencing. European Journal of Endocrinology 2019 180 L1L3. (https://doi.org/10.1530/EJE-18-0852)

    • Search Google Scholar
    • Export Citation
  • 16

    Beijers HJBH, Stikkelbroeck NML, Mensenkamp AR, Pfundt R, van der Luijt RB, Timmers HJLM, Hermus ARMM, Kempers MJE. Germline and somatic mosaicism in a family with multiple endocrine neoplasia type 1 ( MEN1) syndrome. European Journal of Endocrinology 2019 180 K15K19. (https://doi.org/10.1530/EJE-18-0778)

    • Search Google Scholar
    • Export Citation
  • 17

    Cuny T, Pertuit M, Sahnoun-Fathallah M, Daly A, Occhi G, Odou MF, Tabarin A, Nunes ML, Delemer B & Rohmer V et al.Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don’t forget MEN1 genetic analysis. European Journal of Endocrinology 2013 168 533541. (https://doi.org/10.1530/EJE-12-0763)

    • Search Google Scholar
    • Export Citation
  • 18

    Romanet P, Mohamed A, Giraud S, Odou MF, North MO, Pertuit M, Pasmant E, Coppin L, Guien C & Calender A et al.UMD-MEN1 database: an overview of the 370 MEN1 variants present in 1676 patients from the French population. Journal of Clinical Endocrinology and Metabolism 2019 104 753764. (https://doi.org/10.1210/jc.2018-01170)

    • Search Google Scholar
    • Export Citation
  • 19

    Laitman Y, Jaffe A, Schayek H, Friedman E. De novo mutation in MEN1 is not associated with parental somatic mosaicism. Endocrine-Related Cancer 2017 24 L1L3. (https://doi.org/10.1530/ERC-16-0446)

    • Search Google Scholar
    • Export Citation
  • 20

    Pasmant E, Pacot L. Should we genotype the sperm of fathers from patients with ‘de novo’ mutations? European Journal of Endocrinology 2020 182 C1C3. (https://doi.org/10.1530/EJE-19-0759)

    • Search Google Scholar
    • Export Citation
  • 21

    Lin Y, Cai Y, Xu J, Zeng C, Sheng H, Yu Y, Li X, Liu L. ‘Isolated’ germline mosaicism in the phenotypically normal father of a girl with X-linked hypophosphatemic rickets. European Journal of Endocrinology 2020 182 K1K6. (https://doi.org/10.1530/EJE-19-0472)

    • Search Google Scholar
    • Export Citation
  • 22

    de Laat JM, van der Luijt RB, Pieterman CRC, Oostveen MP, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML & Bisschop PH et al.MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. BMC Medicine 2016 14 182. (https://doi.org/10.1186/s12916-016-0708-1)

    • Search Google Scholar
    • Export Citation
  • 23

    Pieterman CRC, Hyde SM, Wu SY, Landry JP, Chiang YJ, Christakis I, Grubbs EG, Fisher SB, Graham PH & Waguespack SG et al.Understanding the clinical course of genotype-negative MEN1 patients can inform management strategies. Surgery 2021 169 175184. (https://doi.org/10.1016/J.SURG.2020.04.067)

    • Search Google Scholar
    • Export Citation
  • 24

    Coppin L, Plouvier P, Crépin M, Jourdain AS, Ait Yahya E, Richard S, Bressac-de Paillerets B, Cardot-Bauters C, Lejeune S & Leclerc J et al.Optimization of next-generation sequencing technologies for von Hippel Lindau (VHL) mosaic mutation detection and development of confirmation methods. Journal of Molecular Diagnostics 2019 21 462470. (https://doi.org/10.1016/j.jmoldx.2019.01.005)

    • Search Google Scholar
    • Export Citation
  • 25

    Coppin L, Grutzmacher C, Crépin M, Destailleur E, Giraud S, Cardot-Bauters C, Porchet N, Pigny P. VHL mosaicism can be detected by clinical next-generation sequencing and is not restricted to patients with a mild phenotype. European Journal of Human Genetics 2014 22 11491152. (https://doi.org/10.1038/ejhg.2013.279)

    • Search Google Scholar
    • Export Citation
  • 26

    Izawa K, Hijikata A, Tanaka N, Kawai T, Saito MK, Goldbach-Mansky R, Aksentijevich I, Yasumi T, Nakahata T & Heike T et al.Detection of base substitution-type somatic mosaicism of the NLRP3 gene with >99.9% statistical confidence by massively parallel sequencing. DNA Research 2012 19 143152. (https://doi.org/10.1093/dnares/dsr047)

    • Search Google Scholar
    • Export Citation
  • 27

    Evans DG, Hartley CL, Smith PT, King AT, Bowers NL, Tobi S, Wallace AJ, Perry M, Anup R & Lloyd SKW et al.Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing. Genetics in Medicine 2020 22 5 35 9. (https://doi.org/10.1038/s41436-019-0598-7)

    • Search Google Scholar
    • Export Citation